DE602007012122D1 - Optimierung der behandlung philadelphia-positiver leukämie mit abl-tyrosinkinasehemmer imatinib - Google Patents

Optimierung der behandlung philadelphia-positiver leukämie mit abl-tyrosinkinasehemmer imatinib

Info

Publication number
DE602007012122D1
DE602007012122D1 DE602007012122T DE602007012122T DE602007012122D1 DE 602007012122 D1 DE602007012122 D1 DE 602007012122D1 DE 602007012122 T DE602007012122 T DE 602007012122T DE 602007012122 T DE602007012122 T DE 602007012122T DE 602007012122 D1 DE602007012122 D1 DE 602007012122D1
Authority
DE
Germany
Prior art keywords
leukemia
cmin
bcr
tyrosine kinase
philadelphia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007012122T
Other languages
English (en)
Inventor
Insa Gathmann
Francois-Xavier Mahon
Mathieu Molimard
Stephane Picard
Yanfeng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39092883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602007012122(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE602007012122D1 publication Critical patent/DE602007012122D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Ecology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602007012122T 2006-09-22 2007-09-20 Optimierung der behandlung philadelphia-positiver leukämie mit abl-tyrosinkinasehemmer imatinib Active DE602007012122D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82662206P 2006-09-22 2006-09-22
US82827806P 2006-10-05 2006-10-05
PCT/US2007/078978 WO2008036792A2 (en) 2006-09-22 2007-09-20 Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
DE602007012122D1 true DE602007012122D1 (de) 2011-03-03

Family

ID=39092883

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007012122T Active DE602007012122D1 (de) 2006-09-22 2007-09-20 Optimierung der behandlung philadelphia-positiver leukämie mit abl-tyrosinkinasehemmer imatinib

Country Status (25)

Country Link
US (2) US20090281113A1 (de)
EP (2) EP2068938B1 (de)
JP (1) JP5735742B2 (de)
KR (1) KR20090065512A (de)
AT (1) ATE495761T1 (de)
AU (1) AU2007299764B2 (de)
BR (1) BRPI0717099A2 (de)
CA (1) CA2662977A1 (de)
CL (1) CL2007002725A1 (de)
CY (1) CY1111356T1 (de)
DE (1) DE602007012122D1 (de)
DK (1) DK2068938T3 (de)
HK (1) HK1133194A1 (de)
HR (1) HRP20110250T1 (de)
IL (1) IL197296A (de)
MA (1) MA30786B1 (de)
MX (1) MX2009003082A (de)
NO (1) NO20091490L (de)
NZ (1) NZ575113A (de)
PL (1) PL2068938T3 (de)
PT (1) PT2068938E (de)
TN (1) TN2009000094A1 (de)
TW (1) TWI398251B (de)
WO (1) WO2008036792A2 (de)
ZA (1) ZA200901220B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2237783B1 (de) * 2008-01-23 2014-11-19 Novartis AG Verfahren zur optimierung der behandlung von durch den tyrosinkinaserezeptor kit vermittelten proliferativen erkrankungen mit imatinib
EP2370078A1 (de) * 2008-12-01 2011-10-05 Novartis AG Verfahren zur optimierung der behandlung von philadelphia-positiver leukämie mit imatinib mesylat
US20110046919A1 (en) * 2009-03-02 2011-02-24 Juliesta Elaine Sylvester Method for accurate measurement of enzyme activities
FR2943418A1 (fr) * 2009-03-17 2010-09-24 Centre Nat Rech Scient Procedes de mesure de la quantite intracellulaire de molecules d'interet intrinsequement fluorescentes par cytometrie en flux et leurs applications
WO2015076213A1 (ja) * 2013-11-22 2015-05-28 独立行政法人国立成育医療研究センター 急性リンパ芽球性白血病の新規キメラ遺伝子ａｔｆ７ｉｐ－ｐｄｇｆｒｂ
WO2017007547A1 (en) 2015-07-07 2017-01-12 Codexis, Inc. Novel p450-bm3 variants with improved activity
IT201900008808A1 (it) 2019-06-13 2020-12-13 Univ Ca Foscari Metodo per la determinazione della concentrazione di 4-[(4-metil-1-piperazinil)metil]-n-(4-metil-3-{[4-(3-piridinil)-2-pirimidinil]-ammino}fenil)benzammide(imatinib) in campioni di plasma
CN114994213A (zh) * 2022-06-28 2022-09-02 北京赛诺浦生物技术有限公司 一种测定人血浆中抗肿瘤药物酪氨酸激酶抑制血药浓度的试剂盒及测定方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
RU2260592C9 (ru) 1999-04-15 2017-04-07 Бристол-Маерс Сквибб Ко. Циклические ингибиторы протеинтирозинкиназ
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
US20050164196A1 (en) * 2002-04-17 2005-07-28 Dressman Marlene M. Methods to predict patient responsiveness to tyrosine kinase inhibitors
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
JP4688876B2 (ja) 2004-06-10 2011-05-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
MY148074A (en) 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant

Also Published As

Publication number Publication date
ATE495761T1 (de) 2011-02-15
TW200822926A (en) 2008-06-01
MX2009003082A (es) 2009-04-01
HRP20110250T1 (hr) 2011-05-31
JP5735742B2 (ja) 2015-06-17
CY1111356T1 (el) 2015-08-05
US20170007605A1 (en) 2017-01-12
JP2010504353A (ja) 2010-02-12
NZ575113A (en) 2012-03-30
HK1133194A1 (en) 2010-03-19
WO2008036792A2 (en) 2008-03-27
EP2068938A2 (de) 2009-06-17
RU2009114856A (ru) 2010-10-27
EP2068938B1 (de) 2011-01-19
CL2007002725A1 (es) 2008-05-16
KR20090065512A (ko) 2009-06-22
TN2009000094A1 (en) 2010-08-19
IL197296A (en) 2011-11-30
ZA200901220B (en) 2010-02-24
TWI398251B (zh) 2013-06-11
CA2662977A1 (en) 2008-03-27
IL197296A0 (en) 2011-08-01
US20090281113A1 (en) 2009-11-12
BRPI0717099A2 (pt) 2013-10-15
DK2068938T3 (da) 2011-04-04
EP2251042A2 (de) 2010-11-17
EP2251042A3 (de) 2012-05-02
AU2007299764B2 (en) 2011-10-13
AU2007299764A1 (en) 2008-03-27
MA30786B1 (fr) 2009-10-01
PL2068938T3 (pl) 2011-06-30
NO20091490L (no) 2009-06-15
WO2008036792A3 (en) 2008-11-13
PT2068938E (pt) 2011-03-23

Similar Documents

Publication Publication Date Title
CY1111356T1 (el) Βελτιστοποιηση της θεραπειας της θετικης στο χρωμοσωμα της φιλαδελφειας λευχαιμιας με ιματινιμπη, εναν αναστολεα κινασης τυροσινης toy abl
Hatoum et al. The unique invasiveness of glioblastoma and possible drug targets on extracellular matrix
Weaver et al. The effect of hearing aids and cochlear implants on balance during gait
Cappuzzo et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
EA201400197A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
EA200600920A1 (ru) Иммуносорбентные исследования крови для оценки пароксизмальных церебральных разрядов
KR20050037510A (ko) 키나제 억제제를 사용하는 암 치료 방법
DE60228592D1 (de) Verfahren zur erkennung von medikamentenempfindlichkeit in patienten mit entzündungskrankheiten
DK1889920T3 (da) In vitro fremgangsmåde atil identifikation af forbindelse atil cancerterapi
Hoyt et al. Sleep quality and depressive symptoms after prostate cancer: The mechanistic role of cortisol.
BRPI0518795A2 (pt) mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio
Smith et al. Acoustic trauma triggers upregulation of serotonin receptor genes
Ortiz-Comino et al. Factors influencing quality of life in survivors of head and neck cancer: a preliminary study
EA201892542A1 (ru) Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19
Kim et al. Novel TECTA mutations identified in stable sensorineural hearing loss and their clinical implications
WO2010066891A3 (en) Method for predicting the response to treatment by tyrosine kinase inhibitors targeting the bcr-abl fusion protein in chronic myeloid leukaemia patients
KR20210137045A (ko) 수면 개선 방법
Wajid et al. EARLY MOLECULAR RESPONSE WITH IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA AND ITS ASSOCIATION WITH BASELINE WHITE BLOOD CELL COUNT AND SPLEEN SIZE: Early Molecular Response With Imatinib Therapy
Mennini et al. Budget impact analysis resulting from the use of dabigatran etexilate in preventing stroke in patients with non-valvular atrial fibrillation in Italy
RU2011122721A (ru) Способ оптимизации лечения хронического миелолейкоза ингибиторами тирозинказы abl
EA201300410A1 (ru) Стратификация страдающих раком пациентов по чувствительности к терапии с использованием ингибиторов ptk2
WO2010065433A1 (en) Method of optimizing the treatment of philadelphia-positive leukemia with imatinib mesylate
CN102526734A (zh) 治疗年龄相关性听力损失的药物组合物及其应用
ATE312612T1 (de) Methode zur optimierung der verwendung von 6- mercaptopurin in der behandlung von immun- vermittelten gastrointestinalen störungen
WO2001045690A3 (en) Use of bvdu for inhibiting the growth of hyperproliferative cells

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN